These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27864489)

  • 1. Protecting Women Against Human Papillomavirus: Benefits, Barriers, and Evidence-Based Strategies to Increase Vaccine Uptake.
    Coyne-Beasley T; Hochwalt BE
    N C Med J; 2016; 77(6):402-405. PubMed ID: 27864489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV 6, 11, 16, 18 vaccine in men. Inadequate assessment.
    Prescrire Int; 2012 Sep; 21(130):208. PubMed ID: 23016251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Papillomavirus Infection and Vaccination.
    Valentino K; Poronsky CB
    J Pediatr Nurs; 2016; 31(2):e155-66. PubMed ID: 26586310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Human papillomavirus nonavalent vaccine. Update 2017].
    Bosch FX; Moreno D; Redondo E; Torné A
    Semergen; 2017; 43(4):265-276. PubMed ID: 28549940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: a registry-based study in Norway.
    Hansen BT; Campbell S; Nygård M
    BMJ Open; 2018 Feb; 8(2):e019005. PubMed ID: 29476028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Papillomavirus and cancers: plea for extending the vaccination to boys].
    Abramowitz L; Descamps P; Denis F; Dommergues MA; Lacau St Guily J; Lefebvre JL; Masse G; Judlin P
    Bull Cancer; 2014; 101(7-8):657-62. PubMed ID: 25091647
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Australia to be first country to vaccinate boys against HPV.
    Kirby T
    Lancet Oncol; 2012 Aug; 13(8):e333. PubMed ID: 23024997
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
    Laprise JF; Drolet M; Boily MC; Jit M; Sauvageau C; Franco EL; Lemieux-Mellouki P; Malagón T; Brisson M
    Vaccine; 2014 Oct; 32(44):5845-53. PubMed ID: 25131743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of decision support on missed opportunities for human papillomavirus vaccination.
    Mayne SL; duRivage NE; Feemster KA; Localio AR; Grundmeier RW; Fiks AG
    Am J Prev Med; 2014 Dec; 47(6):734-44. PubMed ID: 25455116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of human papillomavirus vaccine coverage: a state-level analysis.
    Moss JL; Reiter PL; Brewer NT
    Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.
    Toh ZQ; Licciardi PV; Fong J; Garland SM; Tabrizi SN; Russell FM; Mulholland EK
    Vaccine; 2015 Sep; 33(39):5042-50. PubMed ID: 26271829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing human papillomavirus vaccine acceptability by tailoring messages to young adult women's perceived barriers.
    Gerend MA; Shepherd MA; Lustria ML
    Sex Transm Dis; 2013 May; 40(5):401-5. PubMed ID: 23588130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ
    Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The human papillomavirus vaccines.
    Ljubojević S
    Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany.
    Rieck T; Feig M; Deleré Y; Wichmann O
    Vaccine; 2014 Sep; 32(43):5564-9. PubMed ID: 25131739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination.
    Conroy K; Rosenthal SL; Zimet GD; Jin Y; Bernstein DI; Glynn S; Kahn JA
    J Womens Health (Larchmt); 2009 Oct; 18(10):1679-86. PubMed ID: 19785564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidemiology behind the HPV vaccine discovery.
    Koutsky L
    Ann Epidemiol; 2009 Apr; 19(4):239-44. PubMed ID: 19344861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.